<DOC>
	<DOCNO>NCT00243399</DOCNO>
	<brief_summary>The purpose study evaluate safety drug oxandrolone ( type androgen steroid ) patient Fanconi anemia ( FA ) , determine drug help treatment bone marrow failure patient . Androgen steroid male hormone stimulate production red blood cell ( cell carry oxygen blood ) platelet ( cell help blood clot ) .</brief_summary>
	<brief_title>Oxandrolone Treatment Bone Marrow Aplasia Fanconi Anemia</brief_title>
	<detailed_description>The primary purpose study evaluate safety drug oxandrolone patient Fanconi anemia ( FA ) , secondarily determine drug help treatment bone marrow failure patient . It hop oxandrolone less side effect oxymetholone , androgen use frequently short-term treatment bone marrow failure FA patient . Subjects enrol approximately 18 30 month ( 12 - 24 month treatment 6 month additional monitoring ) . The oxandrolone start dose 0.04mg/kg/day . Study monitor include weekly complete blood count , monthly serum chemistry lab , quarterly physical examination include virilization exam liver ultrasound . Semi-annually , hand radiograph obtain bone maturation behavioral assessment conduct detect aggressive behavior mood change . If improvement n subject 's blood count note 4 month therapy , dose increase 0.08mg/kg/day period 4 month . If improvement note total eight month , oxandrolone discontinue . If blood count show improvement , drug continue minimum twelve month . Subjects may remain study receive total 24 month therapy response blood count without unacceptable side effect . Post-treatment monitoring include blood work ultrasound every three month , hand radiograph six month .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Oxandrolone</mesh_term>
	<criteria>1 . Patients must diagnose Fanconi anemia document positive test increase chromosomal breakage mitomycin C diepoxybutane . 2 . At least follow peripheral blood cytopenia : ( without transfusion ) Absolute neutrophil count &lt; 500/mm3 Platelet count &lt; 30,000/mm3 Hemoglobin &lt; 8.0 gm/dl 3 . Negative pregnancy test hCG testing , childbearing potential . 4 . Agreement use medically approve form birth control , childbearing potential . 5 . Signed informed consent patient legally authorize representative . 6 . Patients must 14 kg . 7 . Male patient include time puberty . With onset puberty , include testosterone level reach 100 ng/dl time exclude study . 1 . Malignancy 2 . Concurrent enrollment study use investigational drug . 3 . Concurrent use anticoagulant . 4 . Use androgen therapy within last three month . 5 . Patients severe liver disease define SGOT SGPT great equal 2.5x upper limit normal total bilirubin great equal 1.5x upper limit normal . 6 . Patients renal disease define serum creatinine great equal 1.5 x upper limit normal age . 7 . Patients less 14 kg . 8 . Patients fail previous therapy oxymetholone .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Fanconi anemia</keyword>
	<keyword>FA</keyword>
</DOC>